ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
ARS Pharmaceuticals (Nasdaq: SPRY) will participate in the Piper Sandler 37th Annual Healthcare Conference in New York, December 2-4, 2025.
Rhea-AI Summary
ARS Pharmaceuticals (Nasdaq: SPRY) will participate in the Piper Sandler 37th Annual Healthcare Conference in New York, December 2-4, 2025.
Company executives Richard Lowenthal, Co-Founder, President and CEO, and Eric Karas, Chief Commercial Officer, will take part in a fireside chat on Wednesday, December 3 at 2:30 pm ET with Piper Sandler analyst David Amsellem. Management will hold one-on-one investor meetings. A live webcast of the fireside chat will be available on the company website and a replay will be archived for 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – SPRY
On Nov 26, the day this news came out, SPRY closed 3.13% above the previous close.
Data tracked by StockTitan Argus for the Nov 26 session.
Key Figures
- Conference edition
- 37th Annual
- Piper Sandler Healthcare Conference
- Conference dates
- December 2–4, 2025
- Piper Sandler Healthcare Conference schedule
- Fireside chat time
- 2:30 pm ET
- December 3 investor fireside chat
- Webcast replay period
- 90 days
- Archived replay of Piper Sandler fireside chat
Historical Context
-
Announcement of Piper Sandler healthcare conference fireside chat and investor meetings.
-
Q3 2025 financials and neffy commercial progress with higher revenue and losses.
-
Launch of Get neffy on Us program to expand access to neffy.
-
Real-world neffy data presentations at ACAAI annual scientific meeting.
-
Scheduling of Q3 2025 conference call and webcast for investors.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
anaphylaxis medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced its participation at the Piper Sandler 37th Annual Healthcare Conference, December 2-4, 2025, in New York.
Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer will participate in a fireside chat on Wednesday, December 3 at 2:30 pm ET with Piper Sandler analyst David Amsellem. Company management will also participate in one-on-one meetings with investors.
A live webcast of the fireside chat will be available here, and in the Investors & Media section of the Company’s website. A replay of the webcast will be archived on the Company’s website for 90 days.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
Investor Contact:
Justin Chakma, ARS Pharma
justinc@ars-pharma.com
Media Contact:
Christy Curran, Sam Brown Inc.
christycurran@sambrown.com
615.414.8668
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.